phosphorus has been researched along with paricalcitol in 68 studies
| Studies (phosphorus) | Trials (phosphorus) | Recent Studies (post-2010) (phosphorus) | Studies (paricalcitol) | Trials (paricalcitol) | Recent Studies (post-2010) (paricalcitol) |
|---|---|---|---|---|---|
| 48,074 | 1,126 | 17,139 | 516 | 100 | 288 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (7.35) | 18.2507 |
| 2000's | 33 (48.53) | 29.6817 |
| 2010's | 29 (42.65) | 24.3611 |
| 2020's | 1 (1.47) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, AJ; Denda, M; Dusso, AS; Finch, JL; Slatopolsky, E; Takahashi, F | 1 |
| Finch, J; Ritter, C; Slatopolsky, E; Takahashi, F | 1 |
| Arruda, J; Delmez, J; Goldblat, MV; Keshav, G; Lau, A; Lindberg, JS; Llach, F; Sadler, R; Slatopolsky, E | 1 |
| Abboud, H; Gellens, ME; González, EA; Hamm, LL; Lindberg, J; Martin, KJ | 1 |
| Brown, AJ; Finch, JL; Slatopolsky, E | 1 |
| Acchiardo, SR; González, EA; Lindberg, J; Martin, KJ; Soltanek, C; Valdin, JR | 1 |
| Llach, F; Yudd, M | 1 |
| Abraham, M; Batlle, D; Lerma, E; McCormmick, D; Sprague, SM | 1 |
| González, EA; Martin, KJ | 1 |
| Brown, AJ; Slatopolsky, E | 1 |
| Chmielewski, C; Foerster, D | 1 |
| Cozzolino, M; Finch, JL; Slatopolsky, E | 1 |
| Brookshire, MA; Moe, SM; Russell, R; Zekonis, M | 1 |
| Ahya, SN; Coyne, DW; Giles, K; Grieff, M; Norwood, K; Slatopolsky, E | 1 |
| Arruda, JA; Barton Pai, A; Lau, AH; Lin, S | 1 |
| Lazarus, JM; Lowrie, E; Ofsthun, N; Teng, M; Thadhani, R; Wolf, M | 1 |
| Colussi, G | 1 |
| Kida, Y | 1 |
| Camargo, CA; Hernán, MA; Lazarus, JM; Ofsthun, MN; Teng, M; Thadhani, R; Wolf, M | 1 |
| Cheng, SC; Coyne, DW; Staniforth, ME | 1 |
| Andrés, E; Ballarín, J; Barceló, P; Bover, J; Ortiz-Herbener, F | 1 |
| Hall, MC; Lovato, J; Patton, S; Schwartz, GG; Stindt, D; Torti, FM | 1 |
| Abboud, H; Anger, M; Batlle, D; Coyne, D; Hippensteel, R; Kavanaugh, A; Lunde, N; Melnick, JZ; Palaparthy, RV; Pradhan, RS; Qiu, P; Smolenski, O; Williams, LA | 1 |
| Ahya, SN; Coyne, DW; Giles, K; Joist, HE; Norwood, K; Slatopolsky, E | 1 |
| Drüeke, TB; Landais, P | 1 |
| Budoff, MJ; Kalantar-Zadeh, K; Kilpatrick, RD; Kopple, JD; Kovesdy, CP; Kuwae, N; McAllister, CJ; Regidor, DL; Salusky, IB; Shinaberger, CS | 1 |
| Bedrick, EJ; Hunt, WC; Johnson, HK; Meyer, KB; Rohrscheib, MR; Stidley, CA; Tentori, F; Zager, PG | 1 |
| Boedigheimer, M; Damore, M; Fitzpatrick, D; Haas, K; Henley, C; Kiaei, P; Lacey, DL; Manoukian, R; Martin, D; McNinch, J; Shalhoub, V; Shatzen, E; Twomey, B; Ward, S | 1 |
| Cardús, A; Fernandez, E; Panizo, S; Parisi, E; Valdivielso, JM | 1 |
| Amdahl, M; Benador, N; Goldstein, SL; Greenbaum, LA; Mattingly, S; Melnick, JZ; Paredes, A; Salusky, IB; Williams, LA | 1 |
| Honkanen, TT; Kööbi, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Rantala, IS; Repo, JM; Ruskoaho, HJ; Rysä, JM; Tahvanainen, AM; Tikkanen, I | 1 |
| Kroeger, PE; Ma, J; Nakane, M; Ruan, X; Wu-Wong, JR | 1 |
| Abboud, H; Hamm, LL; Hippensteel, R; Melnick, JZ; Pradhan, RS; Ross, EA; Sprague, SM; Tian, J; Williams, LA | 1 |
| Aguilera-Tejero, E; Guerrero, F; Lopez, I; Martin, D; Mendoza, FJ; Perez, J; Rodriguez, M | 1 |
| Chaudhary, LR; Geurs, T; Hruska, KA; Lund, RJ; Mathew, S | 1 |
| Bolin, A; Dixon, D; Koch, K; Ma, J; Nakane, M; Noonan, W; Reinhart, G | 1 |
| Brandenburg, V; Cozzolino, M | 1 |
| Ali, N; Chittineni, H; Durie, N; Dutka, P; Fishbane, S; Packman, M | 1 |
| Amdahl, M; Andress, DL; Heaney, RP; Lund, RJ; Williams, LA | 1 |
| Gotch, F; Kotanko, P; Levin, NW | 1 |
| Finch, JL; Lane, N; Nakamura, H; Shahnazari, M; Slatopolsky, E; Tokumoto, M; Yao, W | 1 |
| Aires, I; Amaral, T; Borges, M; Cortez, J; Ferreira, A; Ferreira, C; Gil, C; Jorge, C; Matias, PJ | 1 |
| Fourtounas, C | 1 |
| Christensson, A; Fernström, A; Giæver, J; Granroth, B; Hylander, B; Jacobson, SH; Jensen, G; Weiss, L; Wikström, B; Wrege, U | 1 |
| Bernardo, M; Duggal, A; Engstrand, S; Gonzalez, AR; Hariachar, S; Hertel, J; Hunter, J; Kant, KS; Plone, M | 1 |
| Bacevicius, E; Brandi, L; Danielsen, H; Hansen, D; Kreiner, S; Lauridsen, TG; Madsen, JK; Marckmann, P; Meyer-Hofmann, H; Nielsen, JE; Rasmussen, K; Thye-Roenn, P; Tougaard, BG | 1 |
| Awni, WM; Garimella, TS; Klein, CE; Lichtenberger, O; Noertersheuser, PA; Palaparthy, R; Pradhan, RS; Williams, LA | 1 |
| Aguilera-Tejero, E; Guerrero, F; López, I; Montes de Oca, A; Rodríguez, M; Zafra, R | 1 |
| Cerezo Morales, S; Hervás Sánchez, JG; Polo Moyano, A; Prados Garrido, MD | 1 |
| Beato-Coo, L; Blanco-García, R; Bravo-López, JJ; Cossio-Annibar, C; Moreiras-Plaza, M; Nájera-de la Garza, W; Rodríguez-Goyanes, G | 1 |
| Chen, YW; Nakane, M; Wu-Wong, JR | 1 |
| Bajo, A; Barbosa, F; Borràs, M; Fontán, MP; González, T; Ramos, R; Sánchez, E | 1 |
| Coronel-Aguilar, D; Fernández-Viña, A; González-Díaz, I; Núñez-Moral, M; Peláez-Requejo, B; Quintana-Fernández, A; Rodríguez-Suárez, C; Sánchez-Álvarez, JE | 1 |
| Allende, N; Arias, M; García-Unzueta, MT; Izquierdo-Ortiz, MJ; López-Hoyos, M; Martín-de Francisco, ÁL; Piñera-Haces, C; Quintela, E; Toyos, C | 1 |
| Albero-Molina, MD; Álvarez-Avellán, L; del Pozo-Fernández, C; López-Menchero-Martínez, R; Sánchez-Rodríguez, L | 1 |
| Álvarez, V; Bernis, C; Bomback, AS; Coronel, F; de Lorenzo, A; Moya, M; Salanova, L; Sánchez-Tomero, JA | 1 |
| Amdahl, M; Chen, N; Huang, Z; Jiang, G; Khan, S; Li, X; Lin, H; Liu, L; Qian, J; Wang, M; Xing, C; Yan, Y; Yu, X; Zuo, L | 1 |
| Biggar, P; Graf, H; Ketteler, M; Klauser-Braun, R; Kovarik, J; Müller, HW; Seidinger, S; Veres, A | 1 |
| Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Sharma, A | 1 |
| Cazaña-Pérez, V; Domínguez-Pimentel, V; Donate-Correa, J; Martín-Núñez, E; Mora-Fernández, C; Muros-de-Fuentes, M; Navarro-González, JF | 1 |
| Carpenter, TO; Cheng, D; Ellis, BK; Gundberg, CM; Insogna, KL; Olear, EA; Simpson, CA; Zhang, JH | 1 |
| Acosta Martínez, Y; Borrego Utiel, FJ; Bravo Soto, JA; García Álvarez, T; González Carmelo, I; López Jiménez, V; Mazuecos Blanca, MA; Merino Pérez, MJ | 1 |
| Bover, J; Egido, J; Fernández-Giráldez, E; Martínez-Castelao, A; Praga, M; Solozábal, C; Torregrosa, JV | 1 |
| Kalantar-Zadeh, K; Kumar, J; Pahl, M; Schomberg, J; Streja, E; Tran, NT | 1 |
| Fujii, H; Goto, S; Kono, K; Nakai, K; Nishi, S; Yonekura, Y | 1 |
| Ariceta, G; Dell, KM; Dufek, MB; Eldred, A; Greenbaum, LA; Hoppe, B; Lee, HJ; Lerner, G; Linde, P; Warady, BA; Webb, NJA | 1 |
| Akdag, Y; Ersoy, FF; Hoser, H; Kendir, C; Koc, H | 1 |
| Geng, X; Shi, E; Song, Y; Wang, S | 1 |
8 review(s) available for phosphorus and paricalcitol
| Article | Year |
|---|---|
Strategies to minimize bone disease in renal failure.
Topics: Animals; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Ergocalciferols; Humans; Hyperparathyroidism; Osteoporosis; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency; Vitamin D | 2001 |
Vitamin D analogs for the treatment of secondary hyperparathyroidism.
Topics: Animals; Calcium; Ergocalciferols; Humans; Hyperparathyroidism; Phosphorus; Rats; Renal Insufficiency; Vitamin D | 2002 |
[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics].
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Calcium; Cinacalcet; Diphosphonates; Drug Therapy, Combination; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Retrospective Studies; Teriparatide; Transforming Growth Factor beta; Vitamin D | 2005 |
Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U".
Topics: Calcium; Cinacalcet; Clinical Trials as Topic; Comorbidity; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcitriol; Treatment Outcome; Vitamins | 2009 |
Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.
Topics: Acetates; Algorithms; Bone Density Conservation Agents; Calcitriol; Calcium; Calcium Compounds; Calcium Metabolism Disorders; Calcium, Dietary; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Dialysis Solutions; Ergocalciferols; Homeostasis; Humans; Intestinal Absorption; Kidney Failure, Chronic; Models, Biological; Phosphorus; Practice Guidelines as Topic; Reference Values; Renal Dialysis; Research Design; Ultrafiltration | 2010 |
Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
Topics: Cardiovascular Diseases; Ergocalciferols; Humans; Hyperparathyroidism; Hypocalcemia; Parathyroid Hormone; Phosphorus; Receptors, Calcitriol; Renal Insufficiency, Chronic; Treatment Outcome; Vitamin D | 2014 |
The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.
Topics: Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Minerals; Parathyroid Hormone; Phosphorus; Renal Insufficiency, Chronic | 2016 |
A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.
Topics: Calcium; Disease-Free Survival; Ergocalciferols; Female; Humans; Male; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Receptors, Calcitriol; Renal Dialysis; Survival Rate | 2020 |
21 trial(s) available for phosphorus and paricalcitol
| Article | Year |
|---|---|
Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calcium; Double-Blind Method; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Vitamin D | 1998 |
Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
Topics: Calcium; Double-Blind Method; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone; Phosphorus | 1998 |
A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Calcium; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Failure, Chronic; Male; Middle Aged; Nausea; Parathyroid Hormone; Phosphorus; Taste Disorders; Time Factors; Vomiting | 2001 |
Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.
Topics: Calcitriol; Calcium; Ergocalciferols; Humans; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2001 |
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Androgens; Antineoplastic Agents; Calcium; Ergocalciferols; Humans; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prostate-Specific Antigen; Prostatic Neoplasms; Vitamin D | 2005 |
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Capsules; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Vitamins | 2006 |
Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Calcium; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis | 2006 |
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Double-Blind Method; Ergocalciferols; Female; Humans; Hyperparathyroidism; Infusions, Intravenous; Kidney Failure, Chronic; Male; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2007 |
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Calcium; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Peritoneal Dialysis; Phosphorus; Placebos; Receptors, Calcitriol; Renal Dialysis; Treatment Outcome | 2008 |
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Creatinine; Double-Blind Method; Ergocalciferols; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Proteinuria; Renal Insufficiency, Chronic; Sample Size; Treatment Outcome; Vitamin D Deficiency | 2009 |
Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.
Topics: Adult; Calcitriol; Calcium; Cross-Over Studies; Ergocalciferols; Female; Humans; Intestines; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Treatment Outcome | 2010 |
Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Capsules; Ergocalciferols; Female; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2012 |
No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial.
Topics: Adult; Aged; Calcium; Cross-Over Studies; Ergocalciferols; Female; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2011 |
Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biological Availability; Calcium; Capsules; Double-Blind Method; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Injections; Male; Middle Aged; Parathyroid Hormone; Peritoneal Dialysis; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2012 |
Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcifediol; Calcium; Drug Therapy, Combination; Ergocalciferols; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2012 |
Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcifediol; Cardiovascular Diseases; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Risk Factors; Vitamin D | 2013 |
Oral paricalcitol as antiproteinuric agent in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C-Reactive Protein; Calcium; Chronic Disease; Creatinine; Ergocalciferols; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Proteinuria; Treatment Outcome; Vitamin D | 2013 |
Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.
Topics: Adult; Aged; Calcium; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Single-Blind Method | 2014 |
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Ergocalciferols; Female; Fibroblast Growth Factor-23; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Bone Density Conservation Agents; Child; Double-Blind Method; Ergocalciferols; Familial Hypophosphatemic Rickets; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Placebos; Prospective Studies; Treatment Outcome; Vitamin D; Young Adult | 2014 |
Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
Topics: Adolescent; Bone Density Conservation Agents; Calcium; Child; Double-Blind Method; Ergocalciferols; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Male; Parathyroid Hormone; Phosphorus; Renal Dialysis; Treatment Outcome | 2017 |
39 other study(ies) available for phosphorus and paricalcitol
| Article | Year |
|---|---|
A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
Topics: Animals; Calcium; Ergocalciferols; Female; Intestinal Mucosa; Intestines; Nephrectomy; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Uremia | 1997 |
Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
Topics: Animals; Calcitriol; Calcium; Cattle; Cells, Cultured; Dose-Response Relationship, Drug; Ergocalciferols; Female; Hyperparathyroidism, Secondary; Intestine, Small; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Uremia | 1998 |
Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone.
Topics: Animals; Bone and Bones; Calcitriol; Calcium; Calcium Channel Agonists; Ergocalciferols; Female; Phosphorus; Rats; Rats, Sprague-Dawley | 1999 |
Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
Topics: Calcitriol; Calcium; Dietary Proteins; Drug Resistance; Ergocalciferols; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Serum Albumin | 2001 |
Severe secondary hyperparathyroidism.
Topics: Aged; Calcium; Drug Monitoring; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Parathyroid Hormone; Phosphorus; Treatment Outcome | 2001 |
Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.
Topics: Animals; Calcium; Ergocalciferols; Female; Male; Parathyroidectomy; Phosphorus; Rats; Rats, Sprague-Dawley; Uremia | 2002 |
Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care.
Topics: Aged; Calciphylaxis; Calcium; Debridement; Epoxy Compounds; Ergocalciferols; Humans; Kidney Failure, Chronic; Leg Ulcer; Male; Phosphorus; Polyamines; Polyethylenes; Renal Dialysis; Sevelamer; Wound Healing | 2002 |
Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
Topics: Adult; Aged; Bone Resorption; Calcitriol; Calcium; Cross-Over Studies; Diet; Drug Administration Schedule; Ergocalciferols; Female; Humans; Hyperparathyroidism; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis | 2002 |
Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients.
Topics: Adult; Calcium; Ergocalciferols; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Phosphorus Metabolism Disorders; Renal Dialysis | 2003 |
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
Topics: Adult; Aged; Aged, 80 and over; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cohort Studies; Ergocalciferols; Female; Follow-Up Studies; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Retrospective Studies; Survival Rate | 2003 |
Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
Topics: Calcitriol; Calcium; Control Groups; Ergocalciferols; Humans; Kidney Failure, Chronic; Phosphorus; Renal Dialysis | 2003 |
Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.
Topics: Calcitriol; Calcium; Ergocalciferols; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Phosphorus; Renal Dialysis | 2003 |
Activated injectable vitamin D and hemodialysis survival: a historical cohort study.
Topics: Calcitriol; Calcium; Cohort Studies; Ergocalciferols; Humans; Injections; Parathyroid Hormone; Phosphorus; Proportional Hazards Models; Renal Dialysis; Retrospective Studies; Survival Analysis; Vitamin D | 2005 |
Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Topics: Calcium; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergocalciferols; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Treatment Outcome | 2005 |
Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.
Topics: Acetates; Calcitriol; Calcium; Calcium Compounds; Chronic Disease; Cinacalcet; Clinical Trials, Phase III as Topic; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic | 2006 |
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.
Topics: Aged; Alkaline Phosphatase; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Ergocalciferols; Female; Humans; Kidney Diseases; Male; Middle Aged; Multivariate Analysis; Parathyroid Hormone; Phosphorus; Predictive Value of Tests; Proportional Hazards Models; Renal Dialysis; Risk Factors; Survival Analysis; Time Factors | 2006 |
Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Retrospective Studies; Risk Factors; Survival Analysis; Vitamin D | 2006 |
Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols.
Topics: Alkaline Phosphatase; Aniline Compounds; Animals; Aorta; Calcinosis; Calcitriol; Calcium; Cattle; Cells, Cultured; Drug Combinations; Ergocalciferols; Gene Expression; Glycerophosphates; Muscle, Smooth, Vascular; Oligonucleotide Array Sequence Analysis; Phenethylamines; Phosphorus; Propylamines; Receptors, Calcitriol; Receptors, Calcium-Sensing; Signal Transduction; Wnt Proteins | 2006 |
Differential effects of vitamin D analogs on vascular calcification.
Topics: Animals; Aorta; Blood Pressure; Bone Density Conservation Agents; Calcinosis; Calcitriol; Calcium; Cells, Cultured; Ergocalciferols; Gene Expression; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nephrectomy; Osteoprotegerin; Parathyroid Hormone; Phosphorus; RANK Ligand; Rats; Rats, Sprague-Dawley; Vascular Diseases; Vitamin D | 2007 |
Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Calcitriol; Calcium; Cardiovascular System; Chronic Disease; Creatinine; Ergocalciferols; Fibrosis; Male; Nephrectomy; Parathyroid Hormone; Peptidyl-Dipeptidase A; Phosphorus; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Renin | 2007 |
Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells.
Topics: Animals; Cell Nucleus; Cells, Cultured; Coronary Vessels; Cytosol; Down-Regulation; Ergocalciferols; Gene Expression Regulation; Humans; Mice; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Oligonucleotide Array Sequence Analysis; Osteopontin; Phosphorus; PPAR gamma; Receptors, Calcitriol; Repressor Proteins; Thrombomodulin; Tissue Distribution; Up-Regulation | 2007 |
The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.
Topics: Animals; Aorta; Calcinosis; Calcitriol; Calcium; Calcium Channel Agonists; Ergocalciferols; Hyperparathyroidism, Secondary; Male; Phosphorus; Rats; Rats, Wistar; Uremia | 2008 |
Vitamin D receptor activators can protect against vascular calcification.
Topics: Animals; Aorta; Aortic Diseases; Bone Density Conservation Agents; Bone Diseases, Endocrine; Calcinosis; Calcitriol; Calcium; Dietary Fats; Ergocalciferols; Female; Femur; Gene Expression; Kidney Failure, Chronic; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Osteoblasts; Phosphorus; Receptors, Calcitriol | 2008 |
Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Topics: Animals; Aorta; Blood Flow Velocity; Calcinosis; Calcium; Ergocalciferols; Hyperparathyroidism, Secondary; Male; Nephrectomy; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Renal Insufficiency, Chronic; Uremia; Vascular Resistance | 2008 |
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Topics: Animals; Biomarkers; Bone Resorption; Calcitriol; Calcium; Cinacalcet; Creatinine; Disease Models, Animal; Ergocalciferols; Female; Fibroblast Growth Factors; Hyperparathyroidism; Hyperphosphatemia; Hypocalcemia; Naphthalenes; Nephrectomy; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Severity of Illness Index; Tibia; Uremia | 2010 |
Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; C-Reactive Protein; Calcitriol; Calcium; Chelating Agents; Cholecalciferol; Chronic Disease; Darbepoetin alfa; Dietary Supplements; Ergocalciferols; Erythropoietin; Female; Hematinics; Humans; Hypertrophy, Left Ventricular; Inflammation Mediators; Kidney Diseases; Male; Middle Aged; Natriuretic Peptide, Brain; Parathyroid Hormone; Phosphorus; Polyamines; Prospective Studies; Renal Dialysis; Serum Albumin; Sevelamer; Time Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency; Vitamins | 2010 |
Paricalcitol for reduction of albuminuria in diabetes.
Topics: Albuminuria; Bone Density Conservation Agents; Diabetic Nephropathies; Ergocalciferols; Humans; Long-Term Care; Phosphorus; Prognosis; Randomized Controlled Trials as Topic | 2011 |
Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
Topics: Aged; Biomarkers, Pharmacological; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chronic Disease; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Kidney Diseases; Male; Middle Aged; Observation; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Sweden | 2011 |
The effect of vitamin D derivatives on vascular calcification associated with inflammation.
Topics: Animals; Aorta; Blood Pressure; Blotting, Western; Bone Density Conservation Agents; Calcinosis; Calcitriol; Calcium; Cells, Cultured; Cytokines; Ergocalciferols; Female; Humans; Inflammation; Lipopolysaccharides; Muscle, Smooth, Vascular; Nephrectomy; Phosphorus; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Uremia; Vascular Diseases | 2012 |
Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
Topics: Aged; Aged, 80 and over; Body Mass Index; Calcium; Chronic Disease; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Evaluation; Endpoint Determination; Ergocalciferols; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2011 |
Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats.
Topics: Animals; Blood Urea Nitrogen; Calcium; Creatinine; Ergocalciferols; Male; Nephrectomy; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Time Factors; Uremia | 2013 |
Effectiveness of treatment with oral paricalcitol in patients on peritoneal dialysis: a Spanish multicenter study.
Topics: Administration, Oral; Adult; Aged; Calcium; Ergocalciferols; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Parathyroid Hormone; Peritoneal Dialysis; Phosphorus; Retrospective Studies; Spain | 2013 |
Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
Topics: Bone Density Conservation Agents; Calcium; Ergocalciferols; Female; Humans; Male; Middle Aged; Peritoneal Dialysis; Peritoneum; Phosphorus; Prospective Studies; Proteins; Proteinuria; Renal Insufficiency, Chronic | 2013 |
Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term.
Topics: Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Ergocalciferols; Female; Follow-Up Studies; Goals; Guideline Adherence; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Peritoneal Dialysis; Phosphorus; Postoperative Complications; Practice Guidelines as Topic; Renal Dialysis; Retrospective Studies | 2013 |
Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
Topics: Aged; Alkaline Phosphatase; Austria; Bone Density Conservation Agents; Calcimimetic Agents; Calcium; Cinacalcet; Ergocalciferols; Female; Germany; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic | 2014 |
Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Cinacalcet; Drug Substitution; Drug Therapy, Combination; Ergocalciferols; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Postoperative Complications; Retrospective Studies | 2015 |
Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alkaline Phosphatase; Calcitriol; Calcium; Disease Management; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Parenteral Nutrition; Phosphorus; Receptors, Calcitriol; Renal Dialysis; Retrospective Studies; Treatment Outcome | 2016 |
Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
Topics: Animals; Aorta; Biomarkers; Bone Density; Bone Diseases; Calcitriol; Calcium; Ergocalciferols; Fibroblast Growth Factors; Gene Expression Regulation; Glucuronidase; Kidney; Kidney Failure, Chronic; Klotho Proteins; Male; Phosphorus; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Vitamin D | 2017 |
Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
Topics: Bone Density Conservation Agents; Calcium; Drug Monitoring; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Turkey | 2019 |